David Patterson, MA, Senior Vice President Quality and Regulatory
David is responsible for directing the development, implementation and maintenance of quality control, quality assurance and regulatory systems and activities across both sites. He has 35 years of experience in the pharmaceutical and medical device business, operating in the United States and Europe for various companies. During his tenure at these positions he has been responsible for the compliance and regulatory approval of several facility expansions and successful inspections by the US FDA, Canadian, European, Japanese and several South American regulatory agencies. Dave is an ASQ certified Quality Engineer and Quality Auditor.
Steve Bagshaw, CEng, FIChemE - Chief Executive Officer
As CEO Steve has global responsibility for all the business activities of FUJIFILM Diosynth Biotechnologies reporting directly to FUJIFILM Corporation in Tokyo. Steve has over 25 years' experience in the UK and US with this company and its predecessors. His previous roles included three years as President of Image Polymers Inc, a joint venture between Mitsui Chemicals and Avecia. Before that he held a number of Business and Operations Management posts. He became a Fellow of the Institute of Chemical Engineers (FIChemE) in January 2014 and chairs the UK Government sponsored Industrial Biotechnology Leadership Forum.
Stephen Taylor, PhD, Senior Vice President, Commercial
Steve is responsible for global sales and business development activities, including customer program management. In the period 1996-2004 he led the creation and growth of the Avecia Biologics business, and previous to this held a number of R&D and management positions in Avecia and its predecessor businesses. Steve has held a number of external roles helping to lead the development of bioscience in the UK, and is a Board Member of the UK's BioIndustry Association (BIA).
Mark Carver, PhD, Senior Vice President R&D and Innovation
Mark leads all Research & Development activities for both RTP and Billingham sites. He has over 30 years' industrial experience in leading research and development programs to develop scaleable and validated manufacturing processes for biotechnology products and biopharmaceuticals. Prior to joining ICI he held a number of research and teaching positions at leading UK universities. He holds a number of external roles helping to lead the development of biotechnology and bioprocessing science in the UK, including sitting on BBSRC's Industrial Biotechnology and Bioenergy Strategy Advisory Panel. Mark was awarded the Donald Medal in 2011 by the Institute of Chemical Engineers for 'outstanding services in biochemical engineering'.
Martin Meeson, Chief Operating Officer, RTP site
Martin is responsible for all delivery operations at the RTP, NC site.
Prior to joining the company in 2007, Martin was for four years Finance Director at Oxford Chemicals, responsible for all aspects of Finance, IT and Purchasing. Prior to joining Oxford Chemicals, Martin held a number of relevant roles between August 2000 and June 2003 at Hibernia Foods and prior to that at ICI/DuPont and KPMG. He is a member of the ICAEW.
John Foy, President & CEO, College Station site
John is responsible for all delivery operations at the College Station, TX site.
He has over 20 years of experience in Engineering, Maintenance, Operations, Business Development and Logistics. Previously he was part of the RTP team to the growth and success of third party manufacturing business through development of robust business practices pertaining to program management, client proposal and contract development and operations planning.
Paul Found, Deputy COO, Billingham site
Paul is responsible for all delivery operations at the Billingham site.
He is a chartered chemical engineer and a lean six sigma Black Belt with over 15 years' experience in chemical, pharmaceutical and biologics manufacturing. Since joining Avecia Biologics in 2003 as senior process engineer, he has held various positions in engineering, business planning and project management until taking on his current role. Prior to joining the company he held various engineering positions with Monsanto Chemicals and GlaxoSmithKline.
Kenji Orihashi, Executive Vice President, Corporate Office - Business Strategy
Kenji is responsible for Mitsubishi Corporation's 20% interest in FUJIFILM Diosynth Biotechnologies and supporting the Commercial Team. He moved from Billingham to RTP in December 2013. Prior to moving from Tokyo to Billingham in October 2011, he was responsible for Global Sales & Marketing, Procurement, Licensing and CMO Business Development of Pharmaceuticals, Agrochemicals and Fine Chemicals at Mitsubishi Corporation and its affiliated companies for more than 25 years.